Barclays raises Illumina price target to $145, maintains Underweight
Barclays analyst Luke Sergott maintains an Underweight rating on Illumina (NASDAQ: ILMN) but raises the price target to $145 from $122, adjusting the firm's valuation outlook for the genomics company.
*this image is generated using AI for illustrative purposes only.
Barclays analyst Luke Sergott has maintained an Underweight rating on Illumina (NASDAQ: ILMN) while raising the price target to $145 from the previous $122. The revised target indicates a shift in the firm's valuation perspective despite the continued negative stance on the stock.
The rating update comes as part of a routine assessment of the genomics company's market position and future earnings potential. Illumina operates in the highly competitive life sciences tools and genetic analysis sectors.
Rating and Price Target Details
The following table outlines the changes in Barclays' recommendation for Illumina:
| Metric | Previous Value | New Value |
|---|---|---|
| Rating | Underweight | Underweight |
| Price Target | $122 | $145 |
The decision to maintain the Underweight rating suggests that while the price target has increased, the stock may still face headwinds relative to its sector peers or broader market indices. The price target revision to $145 implies a specific upside potential based on the company's current trading price.
What specific factors drove Barclays to raise the price target despite maintaining an Underweight rating?
How might Illumina's competitive landscape impact its ability to meet the revised price target?
What upcoming earnings or product launches could influence Illumina's stock performance in the near term?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
